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The abuse of analgesics in the Australian commu-
nity and its role in disease of the heart and alimentary
canal has been recognized since 1907 [1] when it was
noted that "what the drink habit is among men in
Australia, the headache powder is among women."
The initial reports of analgesic nephropathy from
Australia appeared in the early 1960's [2—5], almost
ten years after Spühler and Zollinger in 1953 [6] drew
attention to the association between abuse of phena-
cetin-containing compounds and a form of renal dis-
ease characterized by renal papillary necrosis (RPN)
and chronic interstitial nephritis.
The habit of analgesic abuse and the serious con-
sequences of renal disease and renal failure is a
major public health problem in the Australian com-
munity. Between 4.6% and 45.1% of different sub-
populations in the community consume analgesics
daily, often for inappropriate reasons [7—16].
At the Royal Newcastle Hospital, 407 patients
with analgesic nephropathy have presented over four
years. This represents a third of all patients present-
ing to the renal unit. In Australia, analgesic abuse
causes terminal renal failure in 20% of those treated
by dialysis and transplantation [17], compared to
5.5% in Canada [19] and 3.1% in Europe [20]. In the
U.S.A., analgesic nephropathy was found to be
responsible for 7% of chronic renal disease in one
survey [18]. The autopsy incidence of RPN in major
Australian hospitals is between 3.6 and 20% [2,2 1—
251 and is much higher than that reported from else-
where in the world (0.1 to 4%) [27—35].
Etiology
There is considerable evidence that compound
analgesics are toxic in man, and analgesic nephropa-
thy has been reported from most countries in the
world, including such unlikely places as the Middle
East and Japan [361. In addition to the 407 cases seen
by one of us, more than 3,000 cases of analgesic
nephropathy have been reported in the literature.
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The characteristic analgesic syndrome [25, 37—391,
the specific pathology [26, 40, 41], the repeated
observation that continued analgesic abuse leads to
renal disease and that renal function improves when
patients stop taking analgesics [19, 42—48], and the
association between per capita analgesic consump-
tion and the incidence of analgesic nephropathy in
various countries [381, all support the view that anal-
gesics have very significant nephrotoxicity. The pro-
spective study that was begun in Switzerland in 1963
by Dubach and colleagues shows a small but signifi-
cant risk to the urinary tract from phenacetin-con-
taming mixtures [49]. Experimentally, RPN is read-
ily produced by compound analgesics containing
aspirin [50]. Some investigators, nonetheless, still
question the existence of analgesic-related renal dis-
ease [51—53].
The analgesics commonly abused in Australia are
shown in Table 1 [54]. 94.7% of patients take com-
pound analgesics, but a small proportion of patients
with RPN had only taken individual analgesics
(Table 1). The analgesic compounds associated with
renal disease in some European countries are differ-
ent in that aspirin is commonly replaced by phena-
zone or amidopyrine in analgesic mixtures.
Early reports of analgesic nephropathy blamed
phenacetin as the nephrotoxic agent on the basis that
it was the "common denominator" in the compound
mixtures abused by patients. Some workers cau-
tioned that serious consideration should be given to
the other components in the analgesic mixtures, par-
ticularly aspirin, as they were also potentially
nephrotoxic [55—57].
Direct evidence of the clinical nephrotoxicity of
individual analgesic compounds such as aspirin,
phenacetin, paracetamol, and caffeine is not availa-
ble, because single analgesic agents are rarely
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Table 1. Pattern of analgesic intake in 190 consecutive patients
with analgesic nephropathy
Analgesic compounds
No. of
patients %
Bex Powder®a 71 37.4
Vincents Powder®h 47 24.7
Miltiple compounds 62 32.6
Bex
Vincents
paracetamol
aspinn
indomethacin
phenylbutazonc
Individual compoundse 10 5.3
aspirin (4)
paracetamol (2)
aspirin + paracetamol (1)
aspirin + indomethacin (1)
indomethacin + phenylbutazone (2)
Total 190 100
Bexa = 500 mg of aspirin + 250 mg of phenacetin + 150 mg of
caffeine.
Vincentsx = 504 mg of aspirin + 168mg of salicylamide + 168
mg of caffeine.
Numbers in parentheses denote the number of patients taking
the compounds.
abused. With the possible exception of one case [58],
RPN has not been reported due to phenacetin abuse
alone. In addition to the cases in Table 1, there are,
however, a number of reports of RPN and renal
failure in patients taking aspirin alone [39, 45, 47, 59—
66] (NANRA RS: unpublished observations) and a
lesser number of reports attributed to paracetamol
alone [67, 68] (MAHONEY JF: personal communica-
tion). Paracetamol is the major metabolite of phena-
cetin [69] and is concentrated in the renal papilla
when animals are fed phenacetin [70]. Additional
evidence suggesting that aspirin and paracetamol are
nephrotoxic is the occasional acute deterioration in
renal function and fresh RPN observed in patients
with analgesic nephropathy who stop abusing com-
pound analgesics but continue to take aspirin or
paracetamol [65].
Following withdrawal of phenacetin, Murray in
Glasgow reported a decline in new cases of analgesic
nephropathy [64], Gault in Canada suggested an
arrest in the progression of the renal disease [48],
and Nordenfelt in Sweden claimed a reduction in the
annual mortality from analgesic nephropathy in a
county hospital [71]. Burry in Australia attributed a
decline in the autopsy incidence of RPN to the
change in formulation of compound analgesics [24],
but has since stated that continuing damage is occur-
ring in the absence of phenacetin [72]. The influence
of dialysis and transplantation on mortality and
autopsy rates has not been fully recognized in some
of these studies, and the Scandinavian data cannot
be applied to Australia or other Anglo-Saxon coun-
tries because the nephrotoxicity and analgesic syn-
drome associated with the phenazone-phenacetin-
caffeine mixtures in Sweden differs significantly
from that seen with the aspirin-phenacetin-caffeine
mixture [25].
In Australia, abuse of analgesics is largely con-
fined to two aspirin containing headache powders,
Bex+ and Vincents® (Table 1). In Vincents com-
pound, phenacetin was replaced by salicylamide in
1967, while Bex contained phenacetin until 1976,
when it was replaced by paracetamol. This afforded
an opportunity to study two consecutive groups of
patients who had exclusively abused either Bex
(aspirin, 500 mg; phenacetin, 250 mg; caffeine, 150
mg), or Vincents (aspirin, 504 mg; salicylamide, 168
mg; caffeine, 168 mg) [54]. Their data is summarized
in Table 2. The absence of phenacetin over an eight-
year period from Vincents powder did not appear to
influence the degree of frequency of renal insufficien-
cy in patients. Similar conclusions were also reached
by Buriy, Axelsen, and Trolove [24].
Patients with rheumatoid arthritis are commonly
treated with large amounts of salicylates over many
years and, therefore, provide an opportunity to
assess the clinical nephrotoxicity of aspirin. The
autopsy and biopsy incidence of RPN and chronic
interstitial nephritis in rheumatoid arthritis is high
and varies from 7.8% to 100% (mean, 40.3%) [24, 66,
73—78]; the renal lesions are identical to those seen in
patients with analgesic nephropathy. The renal
lesion in rheumatoid arthritis related to aspirin alone,
however, is milder than that seen in patients who
abuse compound analgesics, and rheumatoid arthri-
tis patients rarely present with severe renal failure.
Attempts to evaluate the nephrotoxicity of aspirin by
renal function tests have been conflicting and incon-
clusive [51, 78—82]. The results of function studies,
however, depend upon the timing and sensitivity of
the tests used [66].
Animal studies have provided ctnsiderable infor-
mation regarding the relative nephrotoxicity of anal-
gesics. Abrahams et al [83,84] and Saker and Kin-
caid-Smith [85] reported the development of typical
RPN in rats that were gavage-fed with an aspirin-
phenacetin-caffeine (APC) mixture. Saker and Kin-
caid-Smith [85] had used a dose of APC (500 mg/kg!
day), which on a weight-for-weight basis, was equiv-
alent to that consumed by some patients with analge-
sic nephropathy. To extend these studies, we devel-
oped a short experimental model of analgesic-
induced RPN in rats [86, 87]. The results from a
number of studies in rats are summarized in Table 3
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Table 2. Comparison of Bex® and Vincents® powder abusers
- Bex® abusers Vincents® abusers
No. of pts
Estimated consumption:
aspirin, kg
phenacetin, kg
salicylamide, kg
caffeine, kg
Age, yr
Female:male ratio
Serum creatinine, mmoles/liter
No. of pts. with renal
insufficiency'
No. of pts.
Estimated consumption:
aspirin, kg
phenacetin, kg
salicylamide, kg
caffeine, kg
Age, yr
Female:male ratio
Serum creatinine, mmoles/liter
No. of pts. with renal
insufficiencyb
Analgesic consumption > 8 yrs
54
11 10
Ii 10
4±4
50.9 10.0
6.4:1
0.39 0.32
42 (77.8%)
Analgesic Consumption > 8 yrs
17
4±4
4±4
1.5 1.5
43.7 11.5
16:1
0.18 0.14
11 (64.7%)
33
10 75±3
5±4
4±4
51.6 10.3
5.6:1
0.32 0.35
24 (72.7%)
14
3.5 3.5
3±3
1.5 1.5
50.9 9.7
1.8:1
0.18 0.14
8(57.1%)
Analgesica Dose, mg/kg/day Duration feeding, weeks
RPN
dehydration water diuresis
APC (Impure)5 900 8—20 13/31 (37.5%) 0/9
APC (Pure)e 900 8—20 6/10 (60%)
A + NAPA + C 900 12—30 3/8 (37.5%) 2/9(22.2%)
A 500 8—20 9/27 (33.3%)
Ad 200 10—66 7/13 (54.8%)
P 3,000 8—20 3/8 (37.5%) 0/10
NAPA 3,000 8—20 3/7 (42.9%)
C 150 8—20 0/10
Phenylbutazone 10 8—20 1/9(11.1%)
Indomethacin 12 12—30 2/7 (28.6%)
Mefenamic acid 100 8—20 6/9 (66.7%)
Phenazone 1,000 12—30 1/8 (12.5%)
Abbreviations used are: A, aspirin; P, phenacetin; NAPA, paracetamol; C, caffeine. A:P (NAPA) :C = 21:21:8.
Impure = 0.1% p-chloracetanilide.
Pure = 0.01 p-chloracetanilide in P.
Cortical scars in 3/13 (23.1%).
[65, 86—89]. The RPN, medullary calcification, and
cortical scarring produced in the animals were identi-
cal to those seen in patients with analgesic
nephropathy.
RPN was readily produced by an APC mixture in
more than a third of animals. The presence of p-
chloracetanilide did not appear to influence the med-
ullary lesion, confirming a previous study by
Schnitzer, Smith, and Golden [90]. When phenacetin
was replaced by paracetamol in an equivalent dose,
the nephrotoxicity of the analgesic mixture was not
reduced, and 37.5% of animals developed frank
RPN. The nephrotoxicity of phenacetin may be re-
lated, therefore, to the concentration of paracetamol,
its major metabolite, in the renal papilla [69, 70].
Experimental RPN with combinations of aspirin and
phenacetin has also been reported by Goldberg et al
[91] and Molland [92]. The nephrotoxicity of phena-
cetin and paracetamol appear to be similar. Massive
doses of phenacetin and paracetamol (3,000 mg/kg!
Values are mean SD. Analgesic consumption is adjusted to the nearest 0.5 kg.
Renal insufficiency = serum creatinine > 0.llmmoles/liter.
Table 3. Experimental renal papillary necrosis (RPN) with individual and compound analgesics
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day) were used in the studies, and the lesions pro-
duced were minor compared with those seen with
APC or aspirin alone. Similar results have been
reported by Clausen [93] and Fordham, Huffines,
and Welt [94]. There have been more than 30 other
studies in a variety of animals designed to assess the
nephrotoxicity of phenacetin and paracetamol, but
they have been uniformly unsuccessful (reviewed by
Nanra and Kincaid-Smith [50]). The doses of phena-
cetin and paracetamol used in these studies ranged
from 200 to 3,000 mg/kg/day, and the period of feed-
ing ranged from 2 to 24 months, whereas aspirin
alone in a dose of 500 mg/kg/day over 8 to 20 weeks
produced severe RPN in 9 out of 27 animals. To
evaluate the nephrotoxicity of low doses of aspirin,
rats were gavage-fed 200 mg/kg/day of aspirin for 10
to 66 weeks. More than half the animals developed
frank RPN; medullary calcification was noted in 5/13
rats and cortical scars, typical of chronic interstitial
nephritis, in 3/13 rats. No toxicity attributable to
caffeine was found in these studies.
Experimental RPN and medullary damage was
also seen with a variety of other nonsteroid antiin-
flammatory agents (Table 3). It has been suggested
that medullary necrosis is a toxic effect common to
nonsteroid antiinfiammatory drugs [50, 87], and that
this form of tissue damage is mediated through
suppression of prostaglandin synthesis in the renal
medulla [95]. RPN with these drugs has also been
reported by other investigators [96—981.
Acute clinical and animal studies with analgesics
and related chemical substances have been shown to
induce tubular epithelial celluria and hematuria, amino-
aciduria, enzymuria, depression of glomerular and
tubular function, acute tubular necrosis, and renal
failure [99—122]. In all of these studies, aspirin
appears to be much more nephrotoxic than either
phenacetin or paracetamol. The relevance of these
acute experiments and somewhat related chemical
substances to the chronic lesion of RPN associated
with the continuous long term ingestion of analgesic
compounds is, however, questionable.
Clinical syndrome and clinicopathological correlations
The clinical syndrome associated with abuse of
analgesic mixtures is now well recognized. With the
exception of one report in which there were more
males than females [123], analgesic nephropathy has
been recognized as a predominantly female disease
[25, 37—39, 47]. The age and sex distribution of 279
patients with analgesic nephropathy is shown in Fig-
ure 1. Analgesic nephropathy may have a familial
tendency [18, 71, 124]. The recent observation that
there is an association between analgesic nephropa-
thy and HLA antigens suggests the presence of an
additional genetic factor [125].
Nonrenal manifestations of the analgesic syn-
drome. Analgesic nephropathy is part of a much
wider clinical syndrome seen in patients who abuse
analgesic mixtures [25].
Gastrointestinal manifestations occur in more than
half the patients, and peptic ulceration, particularly
a giant gastric ulcer, has been reported in up to
35% of patients [19, 37—39, 126—129]. Peptic ulcer
disease occurs exclusively in patients who abuse
aspirin-containing compounds and is, therefore,
absent from the clinical syndrome in Europe.
Hepatocellular injury with single cell necrosis and
abnormal liver function tests may be associated with
large doses of aspirin [131—132].
Approximately 60 to 90% of analgesic nephropa-
thy patients have anemia commonly due to gastroin-
testinal blood loss and chronic renal failure, but other
forms of anemia have also been described [19, 126,
127, 133—137]. Splenomegaly is found in about 10%
of patients [39, 138, 139], The presence of a cyanotic
tinge due to methemoglobinemia and sulfhemoglobi-
nemia is related to p-phenetidine, a metabolite of
phenacetin, and p-chloracetinilide, a contaminant
[90, 133, 140, 141].
Psychological and psychiatric manifestations are
common in patients who abuse analgesics. This is
reflected in the frequency of associated addictive
habits such as purgative abuse [142, 143], smoking,
[127, 142, 144], alcoholism [127, 142], and use of
psychotrophic drugs and sleeping tablets [9, 142].
Using recognized psychological techniques, certain
personality traits and inadequacies have been identi-
fied, and these include introversion and neuroticism
on the background of disturbed family and social
circumstances [145, 146]. Many workers [144, 147,
148] recognize an addictive syndrome [149], and
cessation of analgesic abuse often leads to withdraw-
al features. Organic features also occur, and bizarre
headaches, migraine, dementia, psychosis, halluci-
nations, and reversible electroencephalographic
abnormalities have all been described [45, 150—155].
Ischemic heart disease occurs in over a third of the
patients with nephropathy [39, 1561. It appears to be
related to the duration of the disease, degree of renal
insufficiency, and severity of hypertension and is
commonly associated with generalized athero-
sclerosis.
Pigmentation is a feature in patients with analgesic
nephropathy and is aggravated by uremia and a
sodium-wasting state. The brownish-black appear-
ance of the necrotic papilae and the brown appear-
ance of urine in analgesic abusers is related to
C
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Fig. 1. Age and sex distribution of279 patients with analgesic nephropathy. The female to male ratio is 6.5:1. Analgesic nephropathy is rare
under the age of 30 years, the peak occurrence being in the 4th and 5th decades of life. Dotted bars denote female patients; solid bars denote
male patients.
3-amino-7-ethoxyphenazone, a breakdown product of
phenacetin [157, 158]. A golden-brown lipofuchsin-
like pigment is widely distributed in the brain, heart,
liver, joint cartilage (like ochronosis), skin, kidney,
and lower urinary tract [159—163]. Lipofuchsin is a
highly oxidized polymer of unsaturated fatty acids
[164], and its accumulation in organs is probably
related to the oxidant effect of phenacetin.
Experimental and clinical studies suggest that
analgesic abuse may be incriminated in a number of
possible gonadal- and pregnancy-related effects;
these include postmaturity, due to reduced uterine
prostaglandin, toxemia of pregnancy, teratogenicity,
and congenital malformations and infertility [165—
171].
The prematurely aged appearance in patients with
analgesic nephropathy has been emphasized [25, 38].
The multiorgan dysfunction occurring at an early age
with the prominent presence of wear-and-tear pig-
ment may reflect premature biologic aging.
Renal manifestations of the analgesic syndrome.
Patients with analgesic nephropathy have a predomi-
nant tubulomedullary dysfunction characterized by
an impaired concentrating and acidifying capacity
and a sodium-losing state [163, 172—178]. The func-
tional abnormalities in 33 patients with analgesic
nephropathy, 24 patients with glomerulonephritis,
and 30 control subjects, all with normal creatinine
clearances [178] are summarized in Table 4. Frank
renal tubular acidosis with a minimum urinary pH>
5.7 is only seen in analgesic nephropathy patients
when renal function is impaired. These functional
defects are responsible for a number of common
clinical manifestations in patients—nocturia, poly-
uria, cramps, medullary calcification [25, 45, 163,
179—183], calculus disease [184, 185], uremic bone
disease [186], and systemic acidosis. Dystrophic cal-
cification of necrotic tissue and excessive ingestion
of milk-alkalis because of gastric disturbances con-
tribute to the nephrocalcinosis. The other factors
80
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Table 4. Renal function tests in patients with analgesic nephropathy and glomerulonephritiso
Control
Analgesic
nephropathy Glomerulonephritis
No. of patients
Age, yr
Ccr, mI/minll.73 m2
Max. Uosm, mOsm/kg H?.O
Acidification:
Mm. urine pH > 5.2
Titratable acid, Eq/m//nun/1.73 ni
Ammonium, p.Eq/ml/min/1.73 m2
Bicarbonate, p.Eq/mllmin/1.73 m2
30
34.6 10.1
112.9 21.3
971.5 133.4
0
35.0 8.7
53.1 9.1
1.2 1.4
33
45.4 9.9
98.2 20.3
6550b 152.3
3/30 (10.0%)
261b 5•7
44.3 11.2
0.4 1.7
24
31.0 11.2
114.5 28.3
909.0 110.4
IC/24 (4.2%)
31.6 4.9
56.4 19.5
0.6 1.0
a Values are mean SD.
Significant reduction, P < 0.01.
C Patient with lupus nephritis.
that contribute to stone formation are necrotic papil-
lae, exfoliation of tubular epithelial cells by analge-
sics, urinary tract obstruction, and infection by urea-
splitting organisms, such as proteus.
Urinary tract infections have been reported in 15
to 60% of patients [19, 38, 39, 46, 47, 127, 144, 1631
and may be asymptomatic. A sterile pyuria is seen in
more than three quarters of the patients and may be
related to either occult infection, calculi, or epithelial
celluria. Instrumentation or obstruction in analgesic
nephropathy may lead to septicemia.
Persistent microscopic hematuria is an important
clue to the development of a transitional cell carci-
noma. Although the reports of the association
between analgesic abuse and papillary carcinoma
have come mainly from Europe [187—192], this seri-
ous complication is also recognized in Australia
[193—196] (ORELL S: personal communication,
1976).
Proteinuria has recently been recognized as a sig-
nificant and serious prognostic feature of analgesic
nephropathy [1971. The incidence of proteinuria ris-
es with a decline in renal function, and there is a
significant inverse correlation between proteinuria
and the creatinine clearance (y = 1.93 — 0.15x, P <
0.01). Renal biopsies were available in 23 patients
with analgesic nephropathy and proteinuria; all biop-
sies showed changes of chronic interstitial nephritis.
However, significant glomerular lesions were seen in
16 patients, membranous nephritis was seen in two
patients, focal glomerular sclerosis was seen in nine
patients, and focal glomerular hyalinosis was seen in
14 patients.
The reported incidence of hypertension in analge-
sic nephropathy varies from 15 to 70% [19, 37—39,
46, 47, 126, 127, 144, 145, 1981. Malignant hyperten-
sion has been observed in 6.9% cases of analgesic
nephropathy, and the common occurrence of signifi-
cant clinical salt- and water-depletion in patients with
severe hypertension is of interest (Fig. 2). The mech-
anism of this physiological paradox is not clear, but
depletion of renal medullary vasodilator substances
[199, 2001 and activation of the renin-angiotensin
system may be involved. Atheromatous renal artery
stenosis may also contribute to severe hypertension,
and correction of such a lesion may lead to improve-
ment in blood pressure control and renal function.
Clinical gout has been observed in 4.6% of analge-
sic nephropathy patients with normal renal function
and in 26.5% patients when there is renal insufficien-
cy [2021; the secondary gout appears to be more
common in males.
RPN is the primary event in analgesic nephropa-
thy [29, 41, 95] and results from ischemic and toxic
damage to the interstitial cells, vasae rectae, and
loops of Henle [40, 92, 95, 202, 2031 due to concen-
tration of analgesics by the countercurrent mecha-
nism [70,205,206]. The roles of medullary ischemia,
probably via suppression of prostaglandin synthesis
[951, and the concentration mechanism have been
emphasized in a number of experimental studies [50,
65, 86—89, 207]. Aspirin has a number of intracellular
toxic effects, including interference with the tricar-
boxyiic cycle, oxidative phosphorylation, and
mucopolysaccharide synthesis [107, 208]. Phenace-
tin and paracetamol cause potent oxidative damage
to all membranes, leading to glucose-6-phosphate
dehydrogenase, glutathione, and dihydronicotina-
mide adenine dinucleotide phosphate (NADPH) defi-
ciency, and it has been suggested that the synergism
between aspirin and phenacetin nephrotoxicity may
be explained on the basis of salicylate inhibition of
NADPH supply through the hexose-monophosphate
shunt [91, 209].
Chronic interstitial nephritis is a nonspecific corti-
cal change resulting from obstruction to tubules in
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Fig. 2. Association between salt and water balance, hypertension, and renal function in
analgesic nephropathy. The figure shows a patient admitted with severe hypertension (BP,
175/130 mm Hg). There was salt- and water-depletion, indicated by a fall in weight (68.5 kg) and
low sodium excretion, and deterioration in renal function (serum creatinine, 9.2 mg/lb ml;
serum bicarbonate, 5 mEq/liter). Acute reduction of blood pressure with parenteral diazoxide
and rapid volume expansion with iv. saline led to a weight gain (72.4 kg), improvement of renal
function (serum creatinine, 4.8 mg/100 ml; serum bicarbonate, 22 mEq/liter), and stabilization
of blood pressure which now required minimal therapy with chlorothiazide and reserpine.
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the necrotic medulla [29, 40, 41, 50, 95, 202], and
similar changes may result form experimental papil-
lectomy or ureteric ligation [210, 2111!. In the early
stages, chronic interstitial nephritis may only be seen
in the cortex overlying the necrotic papilla, while the
intervening cortex which is an extension of the col-
umn of Bertin may be entirely normal.
Diagnosis of analgesic nephropathy. The diagno-
sis of analgesic nephropathy is based on a history of
analgesic abuse and demonstration of RPN.
Analgesic abuse may be defined as an intake of 2
kg of aspirin or phenacetin or paracetamol in the
form of an analgesic mixture [25]; the actual con-
sumption of analgesics may be as high as 30 kg of
aspirin or phenacetin. Precise quantitation of analge-
sics may be difficult, and many patients attempt to
conceal and minimize the extent of abuse [13, 38,
127, 142, 144].
The typical features of RPN are usually identified
on an iv. urogram or by retrograde pyelography. A
normal pelvicalyceal system may be due to early and
mild papillary damage or RPN in situ [212—214]. The
relationship between renal function, radiological,
and renal biopsy abnormalities are summarized in
Table 5.
RPN is occasionally confirmed by the demonstra-
tion of a necrotic papilla voided in urine. When the
radiological features are not diagnostic, the demon-
stration of cortical changes of chronic interstitial
nephritis with the prominent presence of lipofuchsin-
like pigment on renal biopsy assists in the confirma-
tion of diagnosis. Occasionally necrotic medulla may
be present in the biopsy tissue.
The radiological features of RPN may be of the
papillary or the medullary types, and the important
features which assist in diagnosis are ring shadows,
medullary cavities, and medullary calcifications
[179—184, 215, 216]. These changes, however, can-
not be distinguished from RPN in conditions such as
diabetes mellitus or sickle cell disease and have to be
differentiated from chronic nonobstructive atrophic
pyelonephritis or "reflux' nephropathy, tuberculo-
sis, obstructive uropathy, pyelogenic cysts, and
medullary sponge kidney. The radiological differen-
tiation between analgesic nephropathy and chronic
pyelonephritis is important, and the criteria that may
assist in this differentiation are detailed elsewhere
[183].
Management and outcome of analgesic nephro-
pathy. The management of acute renal failure due to
RPN involves the immediate control of life-threaten-
ing complications such as hyperkalemia, severe sys-
temic acidosis, and septicemia, and it involves the
establishment of an adequate urine flow by rapid
correction of intravascular volume-depletion and the
use of large doses of a potent diuretic, such as fru-
semide; dialysis may be necessary. Severe hyperten-
sion which may be present is managed independently
of the negative salt and water balance and responds
satisfactorily to parenteral administration of diazox-
ide or clonidine. Attempts to control hypertension by
sodium restriction may lead to persisting oliguria and
terminal renal failure. Ureteric catheterization is
undertaken early to exclude obstruction from necrot-
ic papilae. Recovery from an episode of acute RPN
is commonly followed by a severe salt-losing phase.
Urological procedures are frequently necessary
[217, 218] (Table 6); 86 procedures were carried out
in 70 patients (30.2%). The indications in our series
were diagnostic (31), unexplained reduction in renal
function (14), renal colic (8), hematuria (8), and per-
sistent urinary tract infection (2).
The therapeutic urological procedures in 17
patients (7.3%) were not associated with any mortali-
ty or significant morbidity. Endoscopic extraction of
papillae were more successful with the dormia bas-
ket, and occasionally ureteric catheter drainage of
the renal pelvis for several days was necessary [2 19—
222]. Contrary to the experience of Johnson [218],
pyelolithiotomy was not performed for free nonob-
structing papillae in the renal pelvis, and on several
occasions large papillae disintegrated and were
Table 5. Relationships between renal function, radiological, and renal biopsy abnormalities in analgesic nephropathy
CJFR
Concentration
capacity
+
Acidification
IVP
Size
+ ++ + /+
++ +++ ++RTA ++
++ +++ ++RTA ++
Pelvicalyceal
abnormality
Chronic interstitial
nephntis
+ +1±
++
(RPN in situ)
a Abbreviations used are: GFR, glomerular filtration rate; RTA, renal tubular acidosis; RPN, renal papillary necrosis: IVP, intravenous
pyelography.
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Table 6. Urological procedures in the management of 232 patients
with analgesic nephropathy
No. of
patients
No. of
procedures
Diagnostic procedures
Cystoscopy
Cystoscopy + retrograde
pyelography
Open renal biopsy
6
42
5
6
57
5
Therapeutic procedures
Cystoscopy + ureteric
catheterization
Cystoscopy + extraction
of papillae from ureter
Ureterolithotomy
Pyelolithotomy
Nephroureterectomy
6
4
I
4
2
6
5
I
4
2
Total 70 86
passed uneventfully. The two cases of transitional
cell carcinoma detected in the 232 patients were
successfully treated by nephroureterectomy.
The main principles in the management of chronic
analgesic nephropathy are total avoidance of all non-
steroid antiinflammatory drugs, careful long-term
supervision of hypertension, salt and water balance
and urinary tract infections, and a constant aware-
ness and early detection of serious complications
such as silent urinary tract obstruction and transi-
tional cell carcinoma. Evidence of cessation of anal-
gesic abuse should be obtained by routine screening
of urine and serum of patients for aspirin, phenace-
tin, and paracetamol, and their metabolites [223—
225].
Outcome. The long-term outlook of patients with
analgesic nephropathy is optimistic if patients stop
abusing analgesics, and a 73.8% five-year cumulative
survival in a group of 43 patients with severe renal
failure has been reported [43]. With the exception of
a very small number with severe personality defects,
most patients with analgesic nephropathy can be
persuaded to stop the regular use of analgesics if an
aggressive and positive attitude is adopted in follow-
up management. The factors which contribute to
deterioration in renal function are uncontrolled
malignant hypertension, persistent proteinuria indic-
ative of a glomerular lesion, nephrectomy necessitat-
ed by pyonephrosis or renal papillary carcinoma,
ischemic heart disease with cardiac failure, and con-
tinuing analgesic abuse.
Over a five-year period, 110 patients with terminal
renal failure were accepted for maintenance dialysis
and transplantation, from a population of 500,000; 61
patients (55.5%) had analgesic nephropathy, and 19
Table 7. Causes of death in 31 patients accepted for dialysis with
analgesic nephropathy and terminal renal failure
No. of patients %
Ischemic heart disease 19 61.3
Septicemia 6 19.4
Cerebrovascular accidents 6 19.4
Dissecting aneurysm
Hemopericardium
Carcinoma stomach
Total 34
a There were two causes in three patients.
patients (17.3%) had glomenilonephritis. This is in
striking contrast to similar data from Europe [20].
The analgesic nephropathy group appeared to be
extemely poor risk patients; the overall mortality in
patients with analgesic nephropathy accepted for
dialysis was 50.8%. This was much higher than the
mortality in patients with glomerulonephritis, which
was 15.8% (x2 = 5.9, P <0.025). The causes of death
in the 31 patients with analgesic nephropathy are
shown in Table 7 and appear to be mainly related to
vascular complications.
Summary
Analgesic abuse is a major public health hazard in
Australia, and analgesic nephropathy with conse-
quent terminal renal failure is the underlying cause in
20% of the patients requiring dialysis and transplan-
tation. Analgesics are invariably taken in the form of
compounds and mixtures. In the aspirin-phenacetin-
caffeine (APC) mixture, aspirin appears to be the
major nephrotoxic agent and phenacetin appears to
play a secondary and synergistic role. The renal
disease associated with abuse of analgesics is charac-
teristic and is part of a much wider clinical syn-
drome, the analgesic syndrome, which includes pep-
tic ulcer disease (35%), anemia (60 to 90%),
hypertension (15 to 70%), ischemic heart disease
(35%), psychological and psychiatric manifestations,
pigmentation, and possible gonadal- and pregnancy-
related effects. The primary lesion in analgesic
nephropathy is renal papillary necrosis (RPN), and
this is a nephrotoxic effect common to all nonsteroid
antiinflammatory agents. The most important factor
in the management of patients with analgesic nephro-
pathy is the cessation of analgesic abuse, and this
leads to improvement and stabilization of renal func-
tion. A small proportion of patients will, however,
deteriorate in relation to accelerated hypertension,
persistent proteinuria, ischemic heart disease, and
complications leading to nephrectomy. Patients with
analgesic nephropathy are poor risk patients and
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have a poor prognosis, even after dialysis and
transplantation.
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